Key result
Compound I-6602 demonstrated improved anti-Rhinovirus activity and decreased cell toxicity compared to pirodavir, achieving a protection index >700 on HRV14 versus 250 for pirodavir.
Answers are grounded in this paper and cite their sources.
Novel synthetic derivatives of pirodavir demonstrate improved antiviral protection indices and lower cytotoxicity against human rhinoviruses in vitro.
Picornaviridae represent a very large family of small RNA viruses, some of which are the cause of important human and animal diseases. Since no specific therapy against any of these viruses currently exists, palliative symptomatic treatments are employed. The early steps of the picornavirus replicative cycle seem to be privileged targets for some antiviral compounds like disoxaril and pirodavir. Pirodavir's main weakness is its cytotoxicity on cell cultures at relatively low doses. In this work some original synthetic compounds were tested, in order to find less toxic compounds with an improved protection index (PI) on infected cells. Using an amino group to substitute the oxygen atom in the central chain, such as that in the control molecule pirodavir, resulted in decreased activity against Rhinoviruses and Polioviruses. The presence of an -ethoxy-propoxy- group in the central chain (as in compound I-6602) resulted in decreased cell toxicity and in improved anti-Rhinovirus activity. This compound actually showed a PI >700 on HRV14, while pirodavir had a PI of 250. These results demonstrate that modification of pirodavir's central hydrocarbon chain can lead to the production of novel derivatives with low cytotoxicity and improved PI against some strains of Rhinoviruses.
No takes yet. Share an insight, caveat, or question.
Laconi et al. (2011) studied Human Rhinoviruses infection. Compound I-6602 vs. Pirodavir was evaluated on Protection index (PI) on infected cells (HRV14). Compound I-6602 demonstrated improved anti-Rhinovirus activity and decreased cell toxicity compared to pirodavir, achieving a protection index >700 on HRV14 versus 250 for pirodavir.
Synapse has enriched 10 related papers. Consider them for comparative context: